Semnur Pharmaceuticals, Inc. (SMNR)

Market Cap	1.84B +1,454.1%
Revenue (ttm)	n/a
Net Income	-155.03M
EPS	-0.97
Shares Out	230.21M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	302
Open	8.00
Previous Close	8.50
Day's Range	8.00 - 8.00
52-Week Range	4.50 - 23.00
Beta	0.17
RSI	38.53
Earnings Date	Apr 21, 2026

About Semnur Pharmaceuticals

Semnur Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate is SP-102, an opioid novel injectable corticosteroid gel formulation for patients with moderate to severe LRP. The company was founded in 2013 and is headquartered in Palo Alto, California. Semnur Pharmaceuticals, Inc. operates as a subsidiary of Scilex Holding Company.

• Industry: Pharmaceutical Preparations
• Founded: 2013
• Employees: 3
• Stock Exchange: OTCMKTS
• Ticker Symbol: SMNR